Leukemia  >>  Phase 1
Welcome,         Profile    Billing    Logout  

838 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukemia
PHI-101-001, NCT04842370: Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Recruiting
1a/1b
42
RoW
PHI-101
Seoul National University Hospital, Pharos iBio Co., Ltd.
Relapsed or Refractory Acute Myeloid Leukemia
05/22
05/22
NCT04840784: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Terminated
1a/1b
9
RoW
ETH-155008, study drug
Shengke Pharmaceuticals Pty Ltd
NHL, Leukemia
05/23
05/23
NCT05003141: PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Recruiting
1a/1b
110
US, RoW
PSB202
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
07/23
01/24
CIRLL study, NCT03420183: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Recruiting
1b
156
US
Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib
Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM)
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
04/19
12/22
V-FAST master, NCT04075747: A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

Completed
1b
57
US
CPX-351, Vyxeos, JZP351, Venetoclax, Venclexta, Midostaurin, Rydapt, Enasidenib, Idhifa
Jazz Pharmaceuticals
Acute Myeloid Leukemia
02/22
09/23
APVO436, NCT03647800: Study of in Patients With AML or MDS

Recruiting
1b
136
US
APVO436
Aptevo Research and Development LLC
AML, MDS
12/22
06/23
NCT04365179: Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

Recruiting
1b
18
US
Nerofe
Immune System Key Ltd, University of Miami Sylvester Comprehensive Cancer Center
Advanced MDS, AML
12/22
12/22
CPDR001X2105, NCT03066648: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Checkmark Data from P1b portion of trial in combination with MBG453 and decitabine for AML/MDS at EHA 2020
Jun 2020 - Jun 2020: Data from P1b portion of trial in combination with MBG453 and decitabine for AML/MDS at EHA 2020
Checkmark In combination with PDR001 for AML or high risk MDS
Feb 2017 - Feb 2017: In combination with PDR001 for AML or high risk MDS
Completed
1b
241
Europe, US, RoW
Decitabine, 5-aza-2'-deoxycytidine, PDR001, spartalizumab, MBG453, sabatolimab, Azacitidine, 5-azacytidine
Novartis Pharmaceuticals
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Preleukemia, Bone Marrow Diseases, Hematologic Diseases, Chronic Myelomonocytic Leukemia
09/23
09/23
ELEVATE, NCT04150887: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Hourglass Sep 2021 - Dec 2021 : P1b data from ELEVATE trial in combination with azacitidine and venetoclax for AML
Active, not recruiting
1b
61
Europe, Canada, US
Cusatuzumab, JNJ-74494550, ARGX-110, Azacitidine, Vidaza, Venetoclax, Venclexta
OncoVerity, Inc., argenx, Janssen Research & Development, LLC
Leukemia, Myeloid, Acute
05/24
05/24
NCT04434196: A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Active, not recruiting
1b
50
Europe, Canada, US
CC-99282, Obinutuzumab
Celgene
Lymphoma, Non-Hodgkin
11/24
05/25
NCT05756777: A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Recruiting
1b
36
US
Gilteritinib, Ivosidenib, Enasidenib
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc.
Acute Myeloid Leukemia (AML)
02/25
02/25
NCT05970822: Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Recruiting
1b
32
RoW
BC3402, Azacitidine
Biocity Biopharmaceutics Co., Ltd.
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
03/25
12/25
ITALLI001, NCT05054465: A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL

Not yet recruiting
1b
48
RoW
Navitoclax, Venetoclax
Israeli Medical Association, Rabin Medical Center, Sheba Medical Center, Rambam Health Care Campus, Tel Aviv Medical Center, Soroka University Medical Center, Shaare Zedek Medical Center, Hadassah Medical Center
Acute Lymphoblastic Leukemia
08/25
08/26
NCT05659732: A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

Recruiting
1b
32
RoW
PEP07
PharmaEngine
Acute Myeloid Leukemia, Lymphoma, Mantle-Cell
12/25
12/25
NCT05342584: Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

Recruiting
1b
99
US
Venetoclax Oral Tablet, Daunorubicin, Cytarabine
Ioannis Mantzaris, AbbVie
Acute Myeloid Leukemia, Myelodysplastic Syndromes
12/28
12/28
ACTRN12623000491662: A Phase 1, Single Centre, Open Label, Single Dose, Pharmacokinetic Study of Erwinaze in Healthy Adult Volunteers

Not yet recruiting
1
12
 
Porton Biopharma Limited, Porton Biopharma Limited
Acute Lymphoblastic Leukemia
 
 
ACTRN12624000115538: A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part A

Not yet recruiting
1
15
 
Enliven Therapeutics, Inc. , Enliven Therapeutics, Inc.
Chronic Myeloid Leukaemia (CML), Parkinson's Disease (PD)
 
 
ACTRN12624000116527: A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part B

Not yet recruiting
1
15
 
Enliven Therapeutics, Inc. , Enliven Therapeutics, Inc.
Chronic Myeloid Leukaemia (CML), Parkinson's Disease (PD)
 
 
CTR20192479: A Phase I clinical trial evaluating HD CD19 CAR-T in patients with refractory or relapsed B-cell acute lymphoblastic leukemia

Not yet recruiting
1
18
China
HD CD19 CAR-T - Huadao (Shanghai) Biopharmaceutical
Huadao (Shanghai) Biopharmaceutical Co., Ltd.
r/r B-ALL (refractory or relapsed B-cell acute lymphoblastic leukemia)
 
 
ACTRN12619000079145: Safety of Immune Cells for Patients with Relapsed Leukaemia or Lymphoma after Chemotherapy

Not yet recruiting
1
20
 
Western Sydney Local Health District, Westmead Hospital, National Health and Medical Research Council
Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukaemia, Non-Hodgkins Lymphoma
 
 
ACTRN12617000740392: Comparative assessment of the absorption of a generic formulation of 600 mg imatinib tablet against the innovator imatinib tablet conducted under fed conditions in healthy male volunteers

Not yet recruiting
1
24
 
Zenith Technology Corp Ltd, Juno Pharmaceuticals Pty Ltd
Leukaemia , Blood Disorders, Cancer
 
 
ACTRN12613000409774: A trial examining the bioavailability of 4 doses of 3 different formulations of Afuresertib - a Gelatin Formulation and Two Prototype Formulations of Afuresertib, in Normal Healthy Volunteers in both the fasted and non-fasted states .

Not yet recruiting
1
36
 
GlaxoSmithKline, GlaxoSmithKline
Oncology (general Cancer). Previous research with this agent has been conducted in Multiple Myeloma. Hodgkins Disease, non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Langerhans Cell Histiocytosis
 
 
ACTRN12624000180516: An Exploratory Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ZE63-0302 in Healthy Volunteers

Not yet recruiting
1
40
 
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC), Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)
Acute Myeloid Leukaemia (AML)
 
 
ACTRN12611000364976: Pharmacokinetics and Safety of Solid Oral Posaconazole(SCH 56592) in Subjects at High Risk for Invasive Fungal Infections

Not yet recruiting
1
160
 
Schering-Plough Pty limited, Schering-Plough Pty limited
High Risk for Invasive Fungal Infection due to: - Expected neutropenia (low white blood cell count) due to chemotherapy for Acute Myelogenous Leukaemia (AML) or Myelodysplastic Syndrome (MDS), High Risk for Invasive Fungal Infection due to: - Hematopoietic stem cell transplant (HSCT) recipients undergoing treatment for graft-versus-host disease (GVHD)
 
 
ACTRN12613000512729: A study to evaluate safety and feasibility of zoledronic acid to prevent joint complication (osteonecrosis) following chemotherapy for acute lymphoblastic leukemia or lymphoma in children and adolescents.

Recruiting
1
10
 
Sydney Children's Hospital Network, Oncology Department The Childrens Hospital at Westmead
Acute lymphoblastic leukemia, Lymphoblastic lymphoma, Osteonecrosis
 
 
ACTRN12624000093583: A Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZE50 0134 in Healthy Volunteers

Recruiting
1
40
 
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC), Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)
Chronic lymphocytic leukemia (CLL)
 
 
ACTRN12619000556145: Maintenance treatment with low-dose lenalidomide after allogeneic stem cell transplantation for patients with acute myeloid leukaemia or myelodysplastic syndrome

Recruiting
1
20
 
Melbourne Health, Celgene
Acute myeloid leukaemia , Myelodysplastic syndrome
 
 
ACTRN12617001579381: Safety of Immune Cells for Patients with Relapsed Leukaemia or Lymphoma after Bone Marrow Transplant

Recruiting
1
20
 
Western Sydney Local Health District, Westmead Hospital, National Health and Medical Research Council
Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukaemia, Non-Hodgkins Lymphoma
 
 
ACTRN12618001090202: Coadministration of Malignancy and Infection specific T cells after allogeneic stem cell Transplant for Acute Leukaemia with CD34+ selected stem cells

Recruiting
1
20
 
Western Sydney Local Health District, Westmead Hospital, Cancer Council New South Wales
Acute Leukaemia, Cytomegalovirus, Epstein-Barr Virus, Varicella Zoster Virus, BK Virus, Influenza virus, Aspergillus
 
 
CTR20191243: Safety and tolerability study of pCAR-19B in CD19-positive R/R B-ALL

Completed
1
12
China
pCAR-19B - Chongqing Precision Biotech
Chongqing Precision Biotechnology Co., Ltd.
CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia
 
 
ACTRN12620001024932: Comparative assessment of the absorption of a test formulation of 1 x 12 mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsule against the innovator 2x 10 mg (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules conducted under fed conditions in healthy male volunteers.

Recruiting
1
18
 
Zenith Technology Corporation Limited, Douglas Pharmaceuticals Ltd
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARa gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated. (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid is for the induction of remission only.
 
 
CTR20202693: Phase I clinical study of GC007g injection in the treatment of relapsed and refractory CD19-positive acute B lymphoblastic leukemia after allogeneic bone marrow transplantation

Completed
1
18
China
GC007G - Gracell
Genxi Biotechnology (Shanghai) Co., Ltd./Suzhou Genxi Biotechnology Co., Ltd.
Relapsed and refractory CD19-positive acute lymphoblastic leukemia
 
 
CTR20210591: Phase I clinical study of anti-CD19 single chain antibody chimeric antigen receptor T cell injection in the treatment of B-cell acute lymphoblastic leukemia

Recruiting
1
18
China
CAR-T-19 injection - Immunotech Biopharm
Beijing Yongtai Ruike Biotechnology Co., Ltd.
Relapsed/refractory B-cell acute lymphoblastic leukemia
 
 
ACTRN12621000762853: CAR T cell therapy for CD19-positive cancer - phase I clinical trial

Recruiting
1
15
 
Metro North Hospital and Health Service, Clinical Excellence Queensland
B cell blood cancers, including non-Hodgkin's lymphoma and leukaemia.
 
 
ACTRN12622000308796: Short-course treatment with venetoclax prior to non-myeloablative conditioning allogeneic stem cell transplantation for patients with haematological malignancies.

Recruiting
1
18
 
Melbourne Health, The Commonwealth of Australia - Medical Research Future Fund (MRFF)
Acute leukaemia (myeloid and/or lymphoid, or biphenotypic), Myelodysplastic syndrome, Chronic lymphocytic leukaemia, B-cell non-Hodgkin lymphoma, Plasma cell myeloma
 
 
CTR20221359: Phase I clinical study of Senl_B19 autologous T cell injection in the treatment of r/r B-ALL

Recruiting
1
18
China
SENL-B19 - SenlangBio
Hebei Senlang Biotechnology Co., Ltd.
Relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia
 
 
ChiCTR-TRC-12002810: Compare the safety of Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed
1
36
 
amifostine+IA ;IA
Peking University People's Hospital; None, Ethics Committee, Peking University People's Hospital
Newly Diagnosed Acute Myeloid Leukemia
 
 
ChiCTR2000028793: Single-center, single-arm study for autologous fully humanized CD22-CAR T cells in the treatment of refractory / relapsed acute B lymphoblastic leukemia

Not yet recruiting
1
10
 
CD22-CART cells
Beijing Boren Hospital; Beijing Boren Hospital, Self-raised
Blood disease
 
 
ChiCTR-OCC-10000978: Clinical application of low density protein microarray for detecting leukemia prognosis related markers

Completed
1
63
 
none ;none ;none
First Affiliated Hospital of Third Military Medical University; Science and Technology Committee, Chongqing, Science and Technology Planning Project, Chongqing
Leukemia
 
 
ChiCTR-TRC-08000102: A perspective multi-centre trial of reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using fludarabine, busulphan, and cytarabine (FBA) conditioning

Completed
1
420
 
(1) related donor: Bulsulfan+cyclophosphamid; (2) unrelated donor: Bulsulfan+cyclophosphamid+anti-thymocyte cell globulin (ATG) ;(1) related donor: Bulsulfan+cyclophosphamid; (2) 2. unrelated donor: Fludarabine+Bulsulfan+cytarabine+anti-thymocyte cell globulin (ATG)
Changhai Hospital; Level of the institution：, Self-financing
acute myeloid leukemia
 
 
NCT00445666: Tumor-Infiltrating Lymphocytes in Treating Patients With Persistent or Recurrent B-Cell Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma After a Previous Donor Stem Cell Transplant

Active, not recruiting
1
36
US
graft-versus-tumor induction therapy, therapeutic tumor infiltrating lymphocytes, cytogenetic analysis, fluorescence in situ hybridization, microarray analysis, polymerase chain reaction, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, conventional surgery
National Cancer Institute (NCI)
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
 
 
NCT00810966: ABT-888 and Cyclophosphamide in Treating Patients With Solid Tumors or Lymphoma That Did Not Respond to Previous Therapy

Active, not recruiting
1
50
US
cyclophosphamide, veliparib, immunologic technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study
National Cancer Institute (NCI)
Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
 
 
CASPALLO, NCT00710892: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene

Active, not recruiting
1
10
US
Allodepleted T Cells
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
11/11
07/26
ChiCTR-ONC-10000894: Nilotinib plus multi-agent chemotherapy for philadelphia chromosome-positive acute lymphoblastic leukemia

Recruiting
1
30
 
Nilotinib plus multi-agent chemotherapy
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences; Novartis pharmaceutical co., Ltd, Novartis pharmaceutical co., Ltd
Philadelphia chromosome-positive acute lymphoblastic leukemia
 
 
ChiCTR-TRC-08000100: A perspective multi-centre random open parallel case-controlled trial of treatment of relapsed and refractory acute myeloid leukemia with Fludarabine, Cytarabine with or without G-CSF

Completed
1
250
 
Fludarabine 30mg/m^2/d d1-5; Cytarabine 1.5g/m^2/d ;Fludarabine 30mg/m^2/d d1-5; Cytarabine 1.5g/m^2/d
Changhai Hospital; None, Self-funding
Acute Myeloid Leukemia
 
 
ATECRAB, NCT00709033: T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL

Active, not recruiting
1
3
US
autologous or syngeneic PBTLs and EBV-CTLs
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
05/12
04/27
ESCAPE1b, NCT01456988: Dasatinib and Cyclosporine in Patients With Chronic Myelogenous Leukemia (CML)

Recruiting
1
12
US
Dasatinib and Cyclosporine
University of Colorado, Denver, National Cancer Institute (NCI), The Leukemia and Lymphoma Society
Chronic Myelogenous Leukemia
12/12
09/13
ChiCTR-ONC-11001697: The correlations of the cytogenetic responses and the molecular responses during imatinib therapy for chronic myelogenous leukemia

Completed
1
600
 
imatinib
Peking University People's Hospital; Peking University People's Hospital, Peking University People's Hospital
chronic myelogenous leukemia
 
 
ChiCTR-ONC-11001698: The quality of life and toxisities in patients with chronic myeloid leukemia during imatinib therapy

Completed
1
600
 
Imatinib
Peking University People's Hospital, Peking University Institute of Hematology; Peking University People's Hospital, Peking University People's Hospital, Peking University Institute of Hematology
Chronic myeloid leukemia
 
 
NCT01727102: Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Active, not recruiting
1
42
US
sunitinib malate, SU11248, sunitinib, Sutent, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aggressive NK-cell Leukemia, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Malignancies, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV Infection, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Osteolytic Lesions of Multiple Myeloma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
05/13
 
ChiCTR-TRC-12002628: An open-label, randomized, phase III trial of homoharringtonine in the treatment of subjects with newly diagnosed acute promyelocytic leukemia

Completed
1
120
 
Induction therapy with combination of all-trans retinoic acid and homoharringtonine. Consolidation therapy after complete response with combination of cytarabine and homoharringtonine. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of all-trans retinoic acid and daunorubicin/idarubicin. Consolidation therapy with combination of cytarabine and daunorubicin/idarubicin or mitoxantrone. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of all-trans retinoic acid and daunorubicin homoharringtonine. Consolidation therapy with combination of cytarabine and daunorubicin and/or homoharringtonine. All patients in the different groups receive the same maintenance therapy ;Induction therapy with combination of all-trans retinoic acid,arsenic trioxide and daunorubicin/idarubicin. Consolidation therapy with combination of cytarabine and daunorubicin/idarubicin or mitoxantrone. All patients in the different groups receive the same maintenance therapy
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences; Level of the institution：, Ministry of Health funding
Adult patients with acute promyelocytic leukemia
 
 
2012-005629-65: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose-finding study

Ongoing
1
15
Europe
Iclusig, Film-coated tablet, Iclusig
University of Birmingham, Bloodwise TAP, Ariad Pharmaceuticals
Chronic Myeloid Leukaemia (CML) in Blast Phase, CML is a cancer of the white blood cells which build up, disrupting the normal balance of cells in the blood and bone marrow. In Blast phase, the cancer invades the bone marrow and other organs., Diseases [C] - Cancer [C04]
 
 
NCT00588991: Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Active, not recruiting
1
12
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Polycythemia Vera, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
02/14
03/25
NCT01139970: Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Active, not recruiting
1
66
US
Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult T Acute Lymphoblastic Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
03/14
02/25
CRETI-NH, NCT00586391: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

Active, not recruiting
1
14
US
CD19CAR-28-zeta T cells, Ipilimumab, Yervoy
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
07/14
07/29
ChiCTR-TNRC-09000309: Imatinib combined with oncovin and dexamethasone for Ph1 positive ALL, and comparison of two treatment methods after first remission

Completed
1
180
 
Induction Therapy: all patients recieve the same induction therapy with Imatinib,vindesine and dexamethasone ;Patients achieve CR, will recieve 3 courses of intensified chemotherapy ;Patient as a candidate for Allo stem cell transplantation will receive transplantation as soon as he/she complete intensify chemotherapy. Otherwise, chemotherapy as maintenance group will be given until transplantation. ;Maintenance Therapy: imatinib plus oncovin and dexamethasone, and intrathecal prevention of CNS leukemia.Maintennance therapy will continue for 2 years.
Department of Hematology of West China Hospital, Sichuan University; Level of the institution：, Department of Hematology West China Hospital
Newly diagnosed adult with Ph1 positive acute lymphoblastic leukemia
 
 
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
1
70
US, Europe
GDC-0199 (ABT-199), Obinutuzumab
Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd
Lymphocytic Leukemia, Chronic
01/15
11/16
NCT01683279: A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

Active, not recruiting
1
6
US
Autologous CD19 CAR+ EGFTt + T cells
Seattle Children's Hospital
B Cell Leukemia
01/15
01/30
NCT00960050: Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Active, not recruiting
1
173
US
polymorphism analysis, laboratory biomarker analysis, medical chart review, assessment of therapy complications
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Leukemia, Lymphoma, Methemoglobinemia, Nonmalignant Neoplasm
05/15
 
NCT00824525: Targeted, Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation

Recruiting
1
48
US
Etoposide, Cytarabine, Busulfan
University of California, San Francisco
Acute Myelogenous Leukemia
06/15
06/16
ChiCTR-PPC-14005297: The pharmacogenomics study of acute myelogenous leukemia

Recruiting
1
1000
 
No
Institution of Clinical Pharmacology, Central South University; Institution of Clinical Pharmacology, Central South, Natural Science Foundation of China
leukemia
 
 
ChiCTR-TRC-13003671: Effect of KangBaiyannian decoction combined with low dose chemotherapy in the treatment of elderly patients with acute myeloid leukemia: a multicenter randomized controlled clinical study

Completed
1
88
 
low dose chemotherapy ;KangBaiyannian decoction + low dose chemotherapy
Zhejiang Provincial Hospital of Traditional Chinese Medicine; State Administration of Traditional Chinese Medicine, Research Project for Practice Development of National TCM Clinical Research Bases
leukemia
 
 
NCT01861314: Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Active, not recruiting
1
15
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
11/15
03/25
2009-012718-35: An open-label, randomised crossover pharmacokinetic, palatability and safety study to assess the bioavailability of a new 6MP oral liquid formulation by comparison to a currently registered 6MP 50 mg adult tablet (part A) followed by an open, non-randomised multiple-doses study with adjusted doses of 6MP oral liquid formulation (part B) in children with acute lymphoblastic leukaemia.

 
1
30
Europe
Loulla, Puri-Nethol, Loulla, Puri-Nethol, Puri-Nethol
Only For Children Pharmaceuticals
Acute Lymphoblastic Leukemia
 
02/13
2011-005023-40: A dose finding study of Romidepsin and Azacitidine in patients with Acute Myeloid Leukaemia (AML)

Ongoing
1
30
Europe
Romidepsin, Azacitidine, Vidaza, Vidaza
University of Birmingham, Celgene Ltd, Leukaemia & Lymphoma Research Trials Acceleration Programme (TAP)
Acute myeloid leukaemia (AML)
 
 
ANCHOR, NCT00840853: Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

Active, not recruiting
1
68
US
CD19CAR/virus specific T cells, Benadryl and Tylenol, Diphenhydramine and acetaminophen
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Non Hodgkin's Lymphoma
04/16
04/31
2011-004901-25: A study to compare the tablet and oral solution formulations of GSK1120212 in cancer patients

 
1
18
NA
GSK1120212,
GlaxoSmithKline Research and Development Ltd, GSK
GSK1120212 is currently being developed for a number of solid tumors, including metastatic BRAF-mutant melanoma (Phase 3), pancreatic cancer (Phase 2) and non small cell lung cancer (Phase 2), and in hematological malignancies, including acute-myeloid leukemia (AML) or chronic myelo-monocytic leukemia (CMML).
 
 
ChiCTR-IPC-15006301: Cytarabine subcutaneous versus continuous infusion in the treatment of newly diagnosed acute myeloid leukemia patients

Not yet recruiting
1
200
 
idarubicin (10mg/ m2/d); d1-3; Ara-C 100mg/ m2/d, subcutaneously, every 12 h on days 1-7 ;idarubicin (10mg/ m2/d); d1-3; Ara-C 100mg/ m2/d, by continuous intravenous infusion on days 1-7
The First Affiliated Hospital, Zhejiang University; Level of the institution：, Investigator
acute myeloid leukemia
 
 
ChiCTR-OPC-14005741: A single-center, single-arm, prospective investigation on the efficacy and safety of the CLAG regimen as salvage therapy for patients with refractory and relapsed acute myeloid leukemia

Recruiting
1
30
 
CLAG regimen
Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, investigator
acute myeloid leukemia
 
 
ChiCTR-OIC-16008110: A multicenter, single-arm, prospective clinical study of the clinical efficacy and safety treatment of refractory/relapse of acute myeloid leukemia (AML) with CLAAG-M

Recruiting
1
50
 
Cladirbine 5mg/m2 CIV 2h D1-5; Cytarabine 15mg/m2 d1-10; Retinoid acid (ATRA) 45mg/m2 po D4-6 15mg/m2 po D7-20 G-CSF300ug IH D0- Mitoxntrone 6mg/m2 D1,D3,D5
ligen，liu; The 5th people's hospital of Shanghai, The 5th people's hospital of Shanghai
Relapse/refractory AML
 
 
NCT02160015: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Active, not recruiting
1
12
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Electrocardiogram, ECG, EKG, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
03/17
07/24
NCT02312102: Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Active, not recruiting
1
22
US
Lenalidomide, Revlimid, Velcade, bortezomib
Massachusetts General Hospital, Celgene Corporation, Millennium Pharmaceuticals, Inc.
Myelodysplastic Syndrome, Acute Myeloid Leukemia
04/17
08/24
ChiCTR-OPC-14005546: Clincal study of interferon-alpha for prevention of relapse after transplantation in Ph+ALL patients with CD34+CD38-CD58- phenotype at diagnosis

Recruiting
1
15
 
IFN-alpha
Peking University People's Hospital; Peking University People's Hospital, self supported
acute lymphoblastic leukemia
 
 
NCT01815749: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Active, not recruiting
1
30
US
autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
01/18
09/24
NCT02091245: Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Active, not recruiting
1
16
US
KPT-330, Selinexor
Dana-Farber Cancer Institute, William Lawrence and Blanche Hughes Foundation, Karyopharm Therapeutics Inc
Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Biphenotypic Leukemia, Refractory Biphenotypic Leukemia, Chronic Myelogenous Leukemia (CML) in Blast Crisis
02/18
12/24
NCT02268851: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Checkmark From P1/1b trial in combination with umbralisib in CLL and mantle cell lymphoma at EHA 2020
Jun 2020 - Jun 2020: From P1/1b trial in combination with umbralisib in CLL and mantle cell lymphoma at EHA 2020
Checkmark From a trial for r/r CLL or MCL at EHA 2020
Jun 2020 - Jun 2020: From a trial for r/r CLL or MCL at EHA 2020
Checkmark Results in combination with ibrutinib for CLL & MCL
More
Completed
1
45
US
TGR-1202, RP5264, Umbralisib, Ibrutinib, Imbruvica, CRA-032765, PCI-32765
Dana-Farber Cancer Institute, TG Therapeutics, Inc., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
05/18
08/23
ChiCTR-OIN-15007668: Open-label, uncontrolled, single-arm pilot study to evaluate cellular immunotherapy using CD19-targeted chimeric antigen receptor engineered T cells in patients with relapsed or refractory CD19+ B cell leukemia

Not yet recruiting
1
30
 
anti-CD19-CAR-T cells
Shanghai Changhai Hospital，The Second Military Medical University; Shanghai GeneChem Co., Ltd., Shanghai GeneChem Co.,Ltd.
relapsed or refractory CD19+ B cell leukemia
 
 
CARTBALL, ChiCTR-OIC-17013081: Clinical study of CAR-T immune cell targeted therapy for recurrent/refractory leukemia and lymphoma

Recruiting
1
20
 
Pretreated with cyclophosphamide; Infusion with 1-5×10^6 CAR-T(+) cell/kg by I.V.
Affiliated Hospital of Nanjing University of Chinese Medicine; Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing Science and Technology Project
Recurrence / refractory CD19 + leukemia, lymphoma
 
 
ChiCTR-OIC-17012526: A multicenter, single-arm, prospective clinical study of the clinical efficacy and safety treatment of refractory/relapse of acute myeloid leukemia (AML) with CLAAG-IDA

Recruiting
1
50
 
Cladribine + Ara C + ATRA + G-CSF + Idarubicin
Tongren Hospital Shanghai Jiao Tong University School Of Medicine; Tongren Hospital Shanghai Jiao Tong University School Of Medicine, Tongren Hospital Shanghai Jiao Tong University School Of Medicine
Relapse/refractory AML
 
 
NCT02484391: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Completed
1
49
US
6,8-Bis(benzylthio)octanoic Acid, Alpha-Lipoic Acid Analogue CPI-613, CPI 613, CPI-613, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Transplantation, HSCT, stem cell transplantation, Mitoxantrone Hydrochloride, CL 232315, DHAD, DHAQ, Dihydroxyanthracenedione Dihydrochloride, Mitoxantrone Dihydrochloride, Mitoxantroni Hydrochloridum, Mitozantrone Hydrochloride, Mitroxone, Neotalem, Novantrone, Onkotrone, Pralifan
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
10/18
02/22
PLAT-04, NCT03244306: A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma

Active, not recruiting
1
4
US
Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
Seattle Children's Hospital
Leukemia
11/18
07/35
ChiCTR-OIC-17013523: Phase I study of autologous anti-CD22 (human derived) chimeric antigen receptor T cells treating refractory and relapsed B acute lymphoblastic leukemia

Recruiting
1
20
 
anti-CD22 Chimeric Antigen Receptor T-Cell Immunotherapy
Beijing Boren Hospital; Beijing Boren Hospital, Beijing Boren Hospital
relapsed or refractory B acute lymphoblastic leukemia
 
 
NCT01638533: Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Active, not recruiting
1
37
Canada, US
Pharmacological Study, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic
National Cancer Institute (NCI), Celgene Corporation
Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
11/18
03/25
ChiCTR-OIC-17013623: Phase I study of autologous anti-CD19 (mice derived) chimeric antigen receptor T cells treating refractory or relapsed B acute lymphoblastic leukemia

Recruiting
1
20
 
anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy
Beijing Boren Hospital; Beijing Boren Hospital, Beijing Boren Hospital
Relapsed or refractory B acute lymphoblastic leukemia
 
 
ChiCTR1800014953: Clinical Study on the Safety and Efficacy of CD19CART Cell Therapy for Refractory B-Cell Leukemia

Recruiting
1
6
 
off-the-shelf CART
Henan Province Cancer Hospital; Innovative Cellular Therapeutics Co., Ltd., Self-raised
r/r B-ALL
 
 
AG120-221-C-001, NCT02632708: Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Checkmark Updated data from P1 trial in combination with chemotherapy in IDH1/2m newly diagnosed AML at ASH 2018 [screenshot]
Dec 2018 - Dec 2018: Updated data from P1 trial in combination with chemotherapy in IDH1/2m newly diagnosed AML at ASH 2018 [screenshot]
Checkmark First data in combination trial of enasidenib or ivosidenib with standard of care intensive chemotherapy at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: First data in combination trial of enasidenib or ivosidenib with standard of care intensive chemotherapy at ASH 2017 [screenshot]
Checkmark Initiation of P1b combination trials for frontline AML
More
Active, not recruiting
1
153
Europe, US
AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide
Institut de Recherches Internationales Servier, Celgene Corporation
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
12/18
07/24
ChiCTR1800020211: Phase I study for autologous anti-CD123 (human derived) chimeric antigen receptor T cells treating refractory or relapsed acute lymphoblastic leukemia

Not yet recruiting
1
10
 
CD123-CART treatment
Beijing Boren Hospital; Beijing Boren Hospital, Beijing Boren Hospital
refractory or relapsed acute lymphoblastic leukemia
 
 
ChiCTR-OIH-17012645: A clinical study of chimeric-antigen-receptor T cells in the treatment of chemo-refractory or relapsing leukemia

Recruiting
1
22
 
CD19-sepecific chimeric antigen receptor T cells (BG-T19)
Pediatrics of Nanfang hospital; Nanfang hospital, Self-raised funds
B cell acute lymphoblastic leukemia/NHL
 
 
NCT06082596: Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Completed
1
32
RoW
BEBT-908 for injection, CUDC-908
BeBetter Med Inc
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma
03/19
03/19
NCT02315612: Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Active, not recruiting
1
123
US
CD22-CAR
National Cancer Institute (NCI)
NHL, Large Cell Lymphoma, Follicular Lymphoma, ALL, B-All, B-precursor ALL, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, B-Non Hodgkin Lymphoma, B-NHL
04/19
06/40
NCT02168140: CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Completed
1
16
US
6,8-bis(benzylthio)octanoic acid, alpha-lipoic acid analogue CPI-613, CPI-613, bendamustine hydrochloride, bendamustin hydrochloride, bendamustine, cytostasan hydrochloride, Treanda
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia
04/19
09/22
ChiCTR-IIh-16008711: Autologous anti-CD19 chimeric antigen receptor T cells treat relapsed or refractory B acute lymphoblastic leukemia

Recruiting
1
20
 
Chimeric Antigen Receptor T-Cell Immunotherapy
Hebei Yanda Ludaopei Hospital; Hebei Yanda Ludaopei Hospital, Hebei Yanda Ludaopei Hospital
relapsed or refractory B acute lymphoblastic leukemia
 
 
FluBuATG, NCT02916979: Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using

Completed
1
20
US
Fludarabine, Busulfan, Rabbit ATG, Methotrexate
Dartmouth-Hitchcock Medical Center
Leukemia, Lymphoid, Leukemia, Myeloid, Myelodysplastic Syndromes, Myelofibrosis, Lymphoma, Malignant, Multiple Myeloma, Waldenstrom Macroglobulinemia
06/19
02/22
2017-003935-12: A phase 1 trial to assess the safety, tolerability and anti-tumor activity of increasing doses of the drugs AZD6738 and gemcitabine in combination.

Not yet recruiting
1
55
Europe
Gemcitabine, AZD6738, L01BC05, Powder for solution for infusion, Film-coated tablet, Concentrate for solution for infusion, Gemcitabine
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, AstraZeneca
Locally advanced or metastatic solid tumour., Solid tumour cancer (any type of cancer apart from leukaemia or lymphoma) which has spread., Diseases [C] - Cancer [C04]
 
 
NCT02280525: Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

Completed
1
8
US
Lenalidomide, CC-5013, Revlimid, Rituximab, Rituxan, Fludarabine, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, Neosar, NK Cells, Cytarabine, Ara-C, Cytosar, DepoCyt, Cytosine Arabinosine Hydrochloride
M.D. Anderson Cancer Center, The Leukemia and Lymphoma Society, Celgene Corporation
Leukemia
07/19
07/19
NCT01163357: Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Active, not recruiting
1
18
US
bortezomib, LDP 341, MLN341, PS-341, VELCADE, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, Melfalan, total marrow irradiation, tacrolimus, Advagraf, FK 506, Prograf, Protopic, sirolimus, AY 22989, RAPA, Rapamune, rapamycin, SILA 9268A, SLM, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
07/19
12/24
NCT03273829: Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed or Refractory Solid Tumors and Leukemias

Recruiting
1
7
US, Canada
Cyclophosphamide, Etoposide, Carfilzomib
Memorial Sloan Kettering Cancer Center
Leukemia, Pediatric Leukemia, Pediatric Solid Tumor
08/19
08/19
ChiCTR-OIC-17013135: Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B cell hematologic malignancies including acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma

Recruiting
1
50
 
CART cell infusion
The third Xiangya Hospital of Central South University; The third Xiangya Hospital of Central South University, Shanghai Youkadi Biological Medicine Technology Co., Ltd
Refractory/Relapsed hematologic malignancies
 
 
STELLA, NCT02475707: Administration of Donor MultiTAA-Specific T Cells for ALL

Active, not recruiting
1
40
US
MultiTAA-specific T cells, Multiple tumor-associated antigen (TAA)-specific T cells
Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital Research Institute
Leukemia, Lymphoblastic (Acute)
10/19
10/24
NCT02477878: Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Active, not recruiting
1
10
US
BPX-501, Rimiducid, AP1903
Bellicum Pharmaceuticals
Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms
01/20
01/33
 

Download Options